Rimona Margalit

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Tel Aviv University, Tel Hashomer Medical Research Infrastructure and Services Ltd.. Active years: 2003-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rimona Margalit. Retrieved from https://idiyas.com/inventor/rimona-margalit

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 18.2

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 19(Granted Patents)

Location History:

Givataim, IL (2003 - 2016)
Givatayim, IL (2009 - 2016)

Company Filing History:

Tel Hashomer Medical Research Infrastructure and Services Ltd.

patents

where one patent can have more than one assignee

Years Active: 2003-2016

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9526705 - Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy (2016-12-27),

2. 9492480 - Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders (2016-11-15),

3. 9421172 - Lipidated glycoprotein particles and methods of use (2016-08-23),

4. 9259474 - Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy (2016-02-16),

5. 8808664 - Lipidated glycoprotein particles and methods of use (2014-08-19),

6. 8632803 - System for delivery of protein in insoluble fibrillar or aggregate form (2014-01-21),

7. 8501237 - Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy (2013-08-06),

8. 8277847 - Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy (2012-10-02),

9. 8178129 - Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostic and therapy (2012-05-15),

10. 7544374 - Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy (2009-06-09),

11. 6630454 - Method and pharmaceutical composition for the treatment of cancer (2003-10-07),

Title: Rimona Margalit: Innovator in Drug Delivery Systems

Introduction

Rimona Margalit is a prominent inventor based in Givatayim, Israel. He has made significant contributions to the field of drug delivery systems, holding a total of 11 patents. His innovative work focuses on developing advanced materials for therapeutic applications.

Latest Patents

Among his latest patents is the invention of lipidated glycosaminoglycan particles. These particles are prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid. They are designed to encapsulate drugs for the treatment of various pathological conditions in animals. Another notable patent involves iron oxide nanoparticles, which are utilized in treating non-infectious inflammatory disorders. This patent outlines a method of treatment using these nanoparticles, along with pharmaceutical compositions and kits that incorporate them.

Career Highlights

Rimona Margalit has worked with esteemed institutions such as Tel Aviv University and Tel Hashomer Medical Research Infrastructure and Services Ltd. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

He has collaborated with notable colleagues, including Dan Peer and Ilia Rivkin. These partnerships have further enriched his research endeavors and expanded the impact of his inventions.

Conclusion

Rimona Margalit is a distinguished inventor whose work in drug delivery systems has the potential to transform therapeutic practices. His innovative patents and collaborations highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.